Sequencing Consumables Market Size, Genomics Research Expansion, and Forecast 2026–2034

Sequencing Consumables Market Overview Analysis By Fortune Business Insights

Market Size and Future Outlook

According to Fortune Business Insights: The global sequencing consumables market was valued at USD 13.02 billion in 2025 and is projected to grow from USD 13.96 billion in 2026 to USD 48.86 billion by 2034, reflecting a robust CAGR of 16.95% over the forecast period. North America dominated the global market, holding a 42.86% share in 2025.

Sequencing consumables encompass the essential disposable materials required for genomic sequencing workflows, including reagents, buffers, enzymes, flow cells, library preparation kits, and reagent cartridges. These products are indispensable for enabling high-throughput genetic analysis across genomics research, personalized medicine, and clinical diagnostics. The rapid expansion of Next-Generation Sequencing (NGS) technologies has been a primary catalyst for consumables demand, further reinforced by the growing use of sequencing in cancer genomics, infectious disease monitoring, and population health programs.

Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/115382

Key Market Trend

The most prominent trend shaping the market is the rising demand for targeted panels and enrichment kits, which enable more precise analysis of specific genomic regions. These products are increasingly essential for personalized medicine and clinical diagnostics, where accuracy and speed are critical. Key players are actively advancing this space — in July 2025, QIAGEN launched its QIAseq xHYB Long Read Panels, a suite of target enrichment solutions for long-read sequencing of genomically complex regions, strengthening its NGS portfolio across both short- and long-read technologies.

Market Dynamics

Drivers: The rising prevalence of chronic diseases and the accelerating adoption of precision medicine are the foremost drivers. Pharmaceutical and biotechnology companies increasingly rely on extensive genomic data to develop personalized therapies, requiring reliable, high-throughput sequencing solutions at scale. Government-backed initiatives further reinforce this momentum — in October 2024, the U.S. National Institutes of Health (NIH) launched a precision medicine clinical trial targeting specific genetic changes in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Restraints: High per-sample costs remain a significant barrier to broader market adoption. Sequencing workflows require multiple consumable categories — library prep kits, quality control reagents, flow cells, and reagent cartridges — and the cumulative cost of repeated runs and validation processes limits uptake among mid-tier hospitals and diagnostic laboratories. Efforts to address this are ongoing; in October 2024, PacBio announced SPRQ chemistry for its Revio system, reducing the cost of a whole human genome to under USD 500 per sample.

Opportunities: The growing emphasis on population genomics and preventive screening programs presents substantial growth potential. Governments and healthcare providers are increasingly investing in genomics-based early detection strategies. In July 2025, the U.K. Government's 10-Year Health Plan for England highlighted the development of a genomics-based population health service aimed at early detection and intervention for high-risk individuals, signaling a major long-term demand driver for sequencing consumables.

Challenges: Supply chain constraints on critical reagents and single-source components pose a persistent operational challenge. Geopolitical disruptions, natural disasters, and production delays can cause significant supply shortages and price volatility, impacting the timely availability of sequencing kits and reagents across the global market.

Segmentation Analysis

By Offering: Sequencing run consumables — including flow cells, sequencing chips, and reagent cartridges — led the market with a 40.1% share in 2025. Their exclusive platform design and necessity in every sequencing run generate sustained, recurring demand. The reagents segment is projected to grow at a CAGR of 14.18% through 2034, driven by expanding research workflows.

By Sequencing Platform: Next-generation sequencing (NGS) was the dominant platform, capturing 80.8% of the market in 2025, owing to its high throughput, cost-efficiency, and versatility across research and clinical applications. Third-generation sequencing is the fastest-growing platform segment, forecast to expand at a remarkable CAGR of 27.85%, supported by advances in long-read sequencing technologies.

By Application: Clinical diagnosis led with a 46.4% market share in 2025, driven by strong demand for accurate, rapid, and cost-effective diagnostic tools and ongoing new product launches. The drug discovery and development segment is projected to grow at a CAGR of 15.09% over the forecast period.

By End User: Hospitals and diagnostic laboratories held the largest share at 46.5% in 2025, driven by the growing integration of genomic technologies into clinical diagnostics, personalized medicine, and disease monitoring. The pharmaceutical and biotechnology companies segment is projected to grow at 15.88% CAGR, reflecting deepening genomic investment across the drug pipeline.

Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/115382

Regional Outlook

North America led the global market at USD 5.58 billion in 2025, with the U.S. accounting for approximately USD 5.17 billion — or 39.7% of global revenues. Advanced genomic research infrastructure and strong government support for biotech activities underpin the region's dominance.

Europe ranked second at USD 3.33 billion in 2025, expected to grow at 16.62% CAGR — the second-highest among all regions. Germany contributed USD 0.76 billion and the U.K. USD 0.64 billion, with growth driven by life sciences funding and expanding personalized medicine initiatives.

Asia Pacific reached USD 2.78 billion in 2025. China was the largest country market in the region at USD 0.98 billion (6.0% of global revenues), followed by Japan at USD 0.45 billion and India at USD 0.36 billion. Increasing R&D investment and demand for genomic diagnostics are driving regional expansion.

Latin America reached USD 0.65 billion and the Middle East & Africa GCC was valued at USD 0.29 billion in 2025, both benefiting from growing biotech research activity and rising adoption of personalized medicine approaches.

Competitive Landscape

The global sequencing consumables market is highly consolidated, with Thermo Fisher Scientific Inc. and Illumina, Inc. holding dominant positions through broad platform footprints and end-to-end consumables ecosystems. QIAGEN and Agilent Technologies strengthen their positions via specialized library prep and target enrichment portfolios. Oxford Nanopore Technologies and PacBio are key players in the expanding long-read sequencing segment. Recent notable developments include Illumina's January 2025 update of the NovaSeq X Series with new kits and software, and 10x Genomics' January 2026 collaboration with Brigham & Women's Hospital to study immune signatures across autoimmune diseases using peripheral blood analysis.